Reuters logo
BRIEF-BioVie says first patient dosed in trial for refractory ascites due to liver cirrhosis
2017年9月28日 / 上午11点18分 / 22 天前

BRIEF-BioVie says first patient dosed in trial for refractory ascites due to liver cirrhosis

Sept 28 (Reuters) - Biovie Inc

* BioVie announces first patient dosed with BIV201 in Phase 2A clinical trial for refractory ascites due to liver cirrhosis Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below